



PRESS RELEASE

Bio-Product and Perspix Biotech cooperate in AI-powered Molecular Drug Design

Nijmegen / Frankfurt, July 2023

Bio-Product, a Dutch protein engineering company and leading provider of molecular design solutions cooperates with Frankfurt based Perspix, a biotech company specialized in the development of next-generation multi-specific antibodies against cancer.

The strategic collaboration aims at further pushing the boundaries of therapeutic antibody engineering. By combining Bio-Product's expertise in protein data analysis and software design with Perspix's advanced experimental and in silico data generation capabilities, the collaboration will

- advance the engineering of novel biotherapeutics,
- enhance AI-powered molecular drug design, and
- drive innovative medicine development for patients in need.

The collaboration represents a significant milestone in the pursuit of scientific progress and underscores the shared commitment of Bio-Product and Perspix Biotech to become frontrunners of AI-driven molecular drug design.

"Together, we accelerate drug discovery through cutting-edge technologies and data-driven insights", emphasizes Henk-Jan Joosten, CEO of Bio-Product.

"Through comprehensive training, our models empower researchers with predictive and generative capabilities, unlocking unprecedented novel therapeutic possibilities", says Matthias Wiedenfels, CEO of Perspix Biotech.

For further media information/interview opportunities please contact:

Dr. José Airas

T +49 (0)177 577 9828

E info@perspixbio.tech

Notes to editors:

Perspix is a biotech company specialized in multi-specific antibodies. Perspix creates next-generation biotherapeutics through an end-to-end automated discovery platform. The company aims to radically accelerate the technical development of biological drug modalities with predictive AI, significantly reducing drug development times and costs. The roPROTix platform automatically generates tens of thousands of in-silico designed modalities and analyses them for key functional and biophysical properties in a parallelized approach. This digitally integrated process generates interrelated and multidimensional datasets of unprecedented quantity and quality, which feed directly into ML algorithms that drive the in-silico design engine.

Perspix is headquartered in the FIZ Frankfurt Innovation Center for Biotechnology, Germany